Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05747703 · ClinicalTrials.gov registry record · NA
Telehealth Treatment for Alcohol Use Disorder
A NA study of Alcohol Use Disorder and Alcoholism, sponsored by Ria Health.
- Active
- Registry status
- NA
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT05747703: Active NA study of Alcohol Use Disorder and Alcoholism, sponsored by Ria Health.
NCT05747703 is a NA study of Alcohol Use Disorder and Alcoholism that is active but no longer recruiting, run by Ria Health. The registered enrollment target is 135 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05747703, a NA study of Alcohol Use Disorder and Alcoholism, is active but no longer recruiting, sponsored by Ria Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a Bluetooth-enabled breathalyzer. Patients are followed for three months during which data are collected, including measures of alcohol consumption and its consequences.
Primary Outcome
Heavy drinking is defined as 5 or more standard drinks per day for men and 4 or more standard drinks per day for women, as assessed by the Timeline Followback.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Ria Treatment Platform
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2026-09 |
| Phase | NA |
What the registry record for NCT05747703 still lists
NCT05747703 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (59% lower).
The record links to 3 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Ria Treatment Platform is the first listed.
NCT05747703 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05747703 about?
NCT05747703 is a clinical study titled "Telehealth Treatment for Alcohol Use Disorder". Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational vide...
What is the current status of trial NCT05747703?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 135 participants. The study started on 2024-01-31. Estimated completion is 2026-09.
What conditions does trial NCT05747703 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Alcoholism, Alcohol Dependence.
What interventions are being tested in trial NCT05747703?
The interventions under investigation include: Ria Treatment Platform (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05747703?
This trial is sponsored by Ria Health, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05747703 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05747703's enrollment target sits among peer trials
135 72nd of 184 higher than 113 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
AAT for Alcohol Use Disorder in Veterans
RECRUITING · NA
-
Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes
RECRUITING · NA
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI